Codex DNA Inc
Change company Symbol lookup
Select an option...
DNAY Codex DNA Inc
SPCE Virgin Galactic Holdings Inc
BBLG Bone Biologics Corp
RPT RPT Realty
CLM Cornerstone Strategic Value Fund
RCI Rogers Communications Inc
ADRA Adara Acquisition Corp
EVTC Evertec Inc
OPEN Opendoor Technologies Inc
XAIR Beyond Air Inc
Go

Company profile

Codex DNA, Inc. is a synthetic biology company focused on enabling researchers to build or write synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA). Its synthetic biology solution addresses the bottlenecks across the multi-step process of building DNA and mRNA, as well as the limitations of existing solutions that prevent the building of DNA and mRNA at a useable scale. Its BioXp system is an end-to-end automated workstation. It has developed and commercialized products, which include BioXp systems, including BioXp 3250 system, BioXp kits for generating an array of synthetic DNA and mRNA, and benchtop reagents that complement the automated synthetic biology workflow applications and workflow solutions. It has launched eight BioXp kits, three benchtop reagent kits, and various other synthetic biology products, including 14 SARS-CoV-2 full-length genomes and RNA controls, as well as its Vmax X2 cells. It has placed approximately 200 BioXp systems globally.

Postmarket

Last Trade
Delayed
$1.94
-0.04 (-2.02%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$1.98
Day's Change
-0.32 (-13.91%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
2.30
Day's Low
1.98
Volume
(Light)
Volume:
140,425

10-day average volume:
274,727
140,425

Company Profile

Codex DNA, Inc. is a synthetic biology company focused on enabling researchers to build or write synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA). Its synthetic biology solution addresses the bottlenecks across the multi-step process of building DNA and mRNA, as well as the limitations of existing solutions that prevent the building of DNA and mRNA at a useable scale. Its BioXp system is an end-to-end automated workstation. It has developed and commercialized products, which include BioXp systems, including BioXp 3250 system, BioXp kits for generating an array of synthetic DNA and mRNA, and benchtop reagents that complement the automated synthetic biology workflow applications and workflow solutions. It has launched eight BioXp kits, three benchtop reagent kits, and various other synthetic biology products, including 14 SARS-CoV-2 full-length genomes and RNA controls, as well as its Vmax X2 cells. It has placed approximately 200 BioXp systems globally.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
4.55x
Price/Book (MRQ)
0.84x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

July 2022
Current Month
336.9K
Previous Month
736.4K
Percent of Float
1.83%
Days to Cover
1.0530 Days

Share Information

DNAY is in a share class of common stock
Float
18.4M
Shares Outstanding
29.4M
Institutions Holding Shares
70
58.94%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

No company officers listed.

Address

  • 9535 Waples Street, Suite 100
  • San Diego, CA 92121-2993
  • Phone: (858) 228-4115
  • Fax: (302) 636-5454
  • https://codexdna.com/

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.